Madrigal Pharmaceuticals, Inc.
HealthcareNASDAQ:MDGL · NASDAQ Global Select
+$5.91 today
Vol 0.20M · Avg 0.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.1B of revenue converted into -$309.4M of net income for the selected period. Gross margin is 93.3% and net margin is -27.0%, showing how much revenue survives after costs and taxes. EPS is $-12.80, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $958.4M +432.1% | $180.1M | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $56.1M +800.8% | $6.2M | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $902.3M +418.8% | $173.9M | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 94.1% -2.4pp | 96.5% | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $388.5M +64.1% | $236.7M -13.1% | $272.4M +11.0% | $245.4M +19.6% | $205.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $813.8M +87.1% | $435.1M +302.3% | $108.1M +124.7% | $48.1M +29.0% | $37.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $1.2B +79.0% | $671.8M +76.6% | $380.5M +29.6% | $293.6M +21.1% | $242.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.5M +37.4% | $1.1M +108.0% | $527.0K +12.8% | $467.0K +15.3% | $405.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$264.5M +41.2% | -$450.1M -24.9% | -$360.4M -23.9% | -$290.9M -20.5% | -$241.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -27.6% +222.3pp | -249.9% | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$300.1M +39.7% | -$497.9M -30.8% | -$380.5M -29.6% | -$293.6M -21.1% | -$242.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -31.3% +245.1pp | -276.4% | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $37.4M -19.9% | $46.7M +138.3% | $19.6M +796.0% | $2.2M +501.9% | $363.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $22.3M +52.1% | $14.7M +15.4% | $12.7M +220.7% | $4.0M | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $11.8M -63.1% | $32.0M +365.8% | $6.9M +485.9% | -$1.8M -379.7% | $636.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$288.3M +38.1% | -$465.9M -24.7% | -$373.6M -26.5% | -$295.4M -22.1% | -$241.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -30.1% +228.6pp | -258.6% | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$288.3M +38.1% | -$465.9M -24.7% | -$373.6M -26.5% | -$295.4M -22.1% | -$241.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -30.1% +228.6pp | -258.6% | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$13 +41.3% | -$22 -9.6% | -$20 -16.0% | -$17 -17.8% | -$15 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$13 +41.3% | -$22 -9.6% | -$20 -16.0% | -$17 -17.8% | -$15 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $22.4M +5.5% | $21.3M +13.8% | $18.7M +9.0% | $17.1M +3.6% | $16.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $22.4M +5.5% | $21.3M +13.8% | $18.7M +9.0% | $17.1M +3.6% | $16.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Moderna, Inc.
NASDAQ:MRNA
$19.91B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.64B
Exelixis, Inc.
NASDAQ:EXEL
$13.38B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.84B
Baxter International Inc.
NYSE:BAX
$10.72B
Bio-Techne Corporation
NASDAQ:TECH
$8.45B
Abivax S.A.
NASDAQ:ABVX
$6.36B
Rhythm Pharmaceuticals, Inc.
NASDAQ:RYTM
$6.05B
Caris Life Sciences, Inc.
NASDAQ:CAI
$5.07B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$210.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MDGL generate?
Madrigal Pharmaceuticals, Inc. (MDGL) reported $958.40M of revenue in fiscal 2025.
Is MDGL profitable?
Madrigal Pharmaceuticals, Inc. (MDGL) reported -$288,284,000.00 of net income, with a net margin of -30.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.